Regeneron presents 44-month Libtayo data while Regeneron stock costs EUR 722.50

Published on 10/26/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year. Regeneron stock costs EUR 722.50 on October 26, 2026 versus EUR 719.90.

Libtayo data and analyst targets

C-POST showed a 37.00 percent lower death risk after 44 months on October 25, 2026.
Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
Regeneron stock trades at EUR 722.50 at 11:50 a.m. CET at Lang & Schwarz on October 26, 2026, 0.36 percent above the Xetra close of October 23, 2026.
Evercore ISI raised its target from USD 850 to USD 900 on October 22, 2026.

Makroaufnahme einer transparenten Antikörper-Proteinstruktur in Blau- und Weißtönen — Regeneron Pharma US75886F1075 fokussiert eine detailreiche Makroaufnahme einer transparenten Antikörper-Proteinstruktur mit feinen Lichtreflexen, Illustration mit AI erstellt.

Regeneron Pharmaceuticals stock (ISIN US75886F1075) was trading at EUR 722.50 at Lang & Schwarz on October 26, 2026 at 11:50 a.m. CET, up 0.36 percent versus the Xetra close of October 23, 2026. The latest company catalyst is longer-term Libtayo data from the C-POST study, published on October 25, 2026 by MarketScreener.

Libtayo data strengthen the pipeline

With a median follow-up of 44 months, Libtayo reduced the risk of death by 37.00 percent versus placebo, compared with a 22.00 percent reduction at 30 months. The phase 3 trial enrolled 415 patients and tested adjuvant treatment for high-risk cutaneous squamous cell carcinoma after surgery and radiation, according to MarketScreener.

The commercial backdrop also has scale. Regeneron's second-quarter 2026 revenue was USD 4.29 billion, while net income attributable to common shareholders was USD 1.30 billion and diluted earnings per share were USD 12.23. Revenue was 16.70 percent higher than the prior-year quarter, based on the standardized financial statement period ended June 30, 2026.

What does the collaboration add?

On October 1, 2026, Regeneron agreed with Sanofi to co-develop and co-commercialize four antibodies. The agreement includes a USD 1.00 billion upfront payment and up to USD 7.00 billion in milestone payments, according to Regeneron. The filing also said a USD 22.00 million acquired research charge was expected to reduce third-quarter GAAP and non-GAAP earnings per diluted share by USD 0.18.

Three milestones shaped the story

On October 1, 2026, the Sanofi collaboration carried USD 1.00 billion upfront and up to USD 7.00 billion in milestones. On October 16, 2026, the European medicines committee recommended a Libtayo regimen of 700 mg every six weeks, as reported by MarketScreener. On October 25, 2026, the C-POST update showed a 37.00 percent lower death risk at 44 months.

Dates investors can mark

Regeneron is scheduled to release third-quarter 2026 results on October 30, 2026, before the US market opens, according to MarketScreener. Evercore ISI raised its price target from USD 850 to USD 900 on October 22, 2026, according to Futu.

Stock holds above the Xetra close

Regeneron stock was trading at EUR 722.50 at Lang & Schwarz on October 26, 2026 at 11:50 a.m. CET, 0.36 percent above the Xetra close of October 23, 2026 at EUR 719.90. The primary listing is on the Nasdaq Global Select Market, where the stock last stood at USD 805.02 on October 23, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.